Core Viewpoint - The company XinNuoWei announced that its subsidiary, Shiyao Group Jushi Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of Dupilumab injection, which will commence shortly [1] Group 1 - The approval pertains to the clinical trial notification for Dupilumab injection [1] - The clinical trials are expected to begin in the near future [1]

Group 1 - The core point of the article highlights the performance of the Huatai Fuhua Medical Service Flexible Allocation Mixed A Fund, which has shown significant returns over various time frames, including a 69.10% return over the past six months and a 65.45% return year-to-date, ranking first in its category [1] - The fund's latest net value is reported at 1.9920 yuan, reflecting a decrease of 0.75% [1] - The fund's top ten stock holdings account for a total of 68.66%, with notable investments in companies such as Heng Rui Pharmaceutical (9.90%) and Ke Lun Pharmaceutical (9.03%) [1] Group 2 - The Huatai Fuhua Medical Service Flexible Allocation Mixed A Fund was established on June 18, 2015, and as of June 30, 2025, it has a total scale of 2.915 billion yuan [1] - The fund manager, Zhang Wei, has a strong background in biomedical studies and extensive experience in the pharmaceutical sector, having held various positions in research and fund management [2]

Group 1 - Beishimei achieved a net profit of 34.71 million yuan in the first half of 2025, a year-on-year increase of 109.70%, with operating income of 776 million yuan, up 16.57% [1] - Tianli Technology reported a net profit of 8.02 million yuan, reversing a loss of 17.91 million yuan from the previous year, despite a 3.54% decline in operating income to 231 million yuan [2] - Jiejie Microelectronics posted a net profit of 247 million yuan, a 15.35% increase, with operating income rising 26.77% to 1.6 billion yuan [3] Group 2 - Henghua Technology's net profit decreased by 3.98% to 6.06 million yuan, despite a significant 78.31% increase in operating income to 373 million yuan [4] - Sunshine Dairy reported a net profit of 59.82 million yuan, an 8.27% increase, with operating income declining by 7.03% to 237 million yuan [5] - Huabang Health's net profit grew by 23.9% to 388 million yuan, with operating income slightly increasing by 0.39% to 5.945 billion yuan [7] Group 3 - Zhongnan Culture's net profit surged by 524.45% to 60.99 million yuan, with operating income increasing by 30.93% to 559 million yuan [8] - Feilong Co. announced the use of 50 million yuan of idle funds for cash management [9] - Mingpu Optical Magnetics received a patent for a new optical communication device [10] Group 4 - Jucan Optoelectronics plans to use up to 400 million yuan of idle funds for cash management [11] - Xinhongye intends to acquire 62% of Yangzhou Shuguang's shares, enhancing its market presence [12] - Victory Co. reported a net profit of 88.44 million yuan, a 7.77% increase, with operating income of 2.158 billion yuan, down 1.64% [14] Group 5 - Aoya Co. reported a net loss of 22.33 million yuan, with operating income declining by 28.29% to 197 million yuan [15] - Furan Energy achieved a net profit of 310 million yuan, a 7.27% increase, with operating income rising by 8.59% to 15.338 billion yuan [16] - Wantong Development's chairman was detained, but the investigation is unrelated to the company's operations [17] Group 6 - An Tong Holdings reported a net profit of 512 million yuan, a 231.49% increase, with operating income of 4.384 billion yuan, up 24.60% [28] - Tailin Microelectronics achieved a net profit of 101 million yuan, a 274.58% increase, with operating income of 503 million yuan, up 37.72% [30] - Zhonghang Shenfei expects a net profit decline of approximately 29.78% to 1.136 billion yuan, with a projected revenue of 14.628 billion yuan, down 32.35% [34] Group 7 - Jingjiawei reported a net loss of 87.61 million yuan, with operating income declining by 44.78% to 193 million yuan [35] - Xizang Tianlu posted a net loss of 112 million yuan, despite a 19.88% increase in operating income to 1.409 billion yuan [36] - Jintian International's net profit decreased by 22.53% to 188 million yuan, with operating income down 14.36% to 1.412 billion yuan [37] Group 8 - Ningbo Jingda plans to invest 20 million yuan to establish a wholly-owned sales subsidiary [38] - Ningbo Jingda reported a net profit of 65.05 million yuan, a 25.77% decrease, with operating income of 401 million yuan, up 1.10% [39] - Shengquan Group achieved a net profit of 501 million yuan, a 51.19% increase, with operating income of 5.351 billion yuan, up 15.67% [40]

Core Viewpoint - The announcement by XinNuoWei regarding the approval of clinical trials for Dupilumab injection marks a significant step in the development of a biosimilar drug targeting IL-4Rα for the treatment of moderate to severe atopic dermatitis in adults [1] Company Summary - XinNuoWei's subsidiary, Shiyao Group Jushi Biopharmaceutical Co., Ltd., has received the clinical trial approval notice from the National Medical Products Administration for Dupilumab injection [1] - Dupilumab injection is a fully human monoclonal antibody drug and is classified as a biosimilar to Dupixent [1] Industry Summary - The drug is categorized under biological products for therapeutic use, specifically as a Class 3.3 application, indicating its relevance in the biopharmaceutical sector [1] - The indication for Dupilumab injection is aimed at treating adults with moderate to severe atopic dermatitis, highlighting the growing demand for effective treatments in this therapeutic area [1]

中国经济网北京8月19日讯 新诺威(300765.SZ)今日股价收报48.88元，跌幅4.55%；昨日股价收报 51.21元，跌幅3.38%。 8月17日，某券商发布研报《新诺威(300765)：持续加码研发 EGFRADC下半年有望启动首个海外 注册临床》称，维持"买入"评级。 （责任编辑：何潇） ...

Group 1 - The stock price of XinNuoWei (300765.SZ) closed at 48.88 yuan, with a decline of 4.55% [1] - The previous day's stock price was 51.21 yuan, reflecting a drop of 3.38% [1] - A brokerage report on August 17 maintained a "buy" rating for XinNuoWei, highlighting the company's ongoing investment in R&D for EGFR ADC and the potential initiation of its first overseas registration clinical trial in the second half of the year [1]

Core Viewpoint - The company XinNuoWei has received approval from the National Medical Products Administration for the clinical trial of Dupilumab injection, a monoclonal antibody drug targeting IL-4Rα, which is a biosimilar to Dupixent, aimed at treating moderate to severe atopic dermatitis in adults [1] Company Summary - XinNuoWei's subsidiary, Shiyao Group Jushi Biopharmaceutical Co., Ltd., has been authorized to conduct clinical trials for Dupilumab injection [1] - The drug is classified as a Class 3.3 biological product for therapeutic use [1] Industry Summary - Dupilumab injection is positioned as a biosimilar to Dupixent, indicating a competitive entry into the market for treatments of atopic dermatitis [1] - The approval for clinical trials reflects ongoing advancements in biopharmaceuticals targeting specific conditions such as atopic dermatitis [1]

新诺威8月19日公告，公司控股子公司巨石生物近日收到国家药品监督管理局核准签发的关于度普利尤 单抗注射液的《药物临床试验批准通知书》，将于近期开展临床试验。度普利尤单抗注射液是一款靶向 IL-4Rα的重组全人源单克隆抗体药物，为达必妥®的生物类似药，适用于治疗成人中重度特应性皮炎。 ...

Core Viewpoint - The company XinNuoWei (300765.SZ) announced that its subsidiary, Shiyao Group Jushi Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of Dupilumab injection, which will commence shortly [1] Group 1 - Dupilumab injection is a recombinant fully human monoclonal antibody drug targeting IL-4Rα, developed as a biosimilar to Dupixent [1] - The drug is classified under Category 3.3 for therapeutic biological products and is intended for the treatment of moderate to severe atopic dermatitis in adults [1] - The research and development of this product adhere to the relevant guidelines for biosimilars, with pharmaceutical and non-clinical research results indicating high similarity in quality, safety, and efficacy compared to the reference drug [1]

Core Viewpoint - The announcement indicates that the subsidiary of the company, Shiyao Group Jushi Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of Dupilumab injection, a biosimilar to Dupixent, aimed at treating moderate to severe atopic dermatitis in adults [1] Group 1 - The clinical trial approval for Dupilumab injection is a significant step for the company in the biopharmaceutical sector [1] - Dupilumab injection is a fully human monoclonal antibody targeting IL-4Rα, which positions it as a competitive product in the treatment of atopic dermatitis [1] - The drug is intended to serve as a biosimilar to Dupixent, which is already established in the market [1]